3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
265
Leukemia, Lymphocytic, Chronic, B-Cell
66
Lymphoma, Large B-Cell, Diffuse
60
Neoplasms, Plasma Cell
50
Lymphoma, Follicular
45
Lymphoma, Mantle-Cell
42
Lymphoma
41
Recurrence
38
Lymphoma, B-Cell, Marginal Zone
31
Leukemia
30
Leukemia, Myeloid, Acute
27
Lymphoma, B-Cell
19
Lymphoma, Non-Hodgkin
17
Myelodysplastic Syndromes
16
Waldenstrom Macroglobulinemia
15
Smoldering Multiple Myeloma
13
Hodgkin Disease
13
Lymphoma, T-Cell, Peripheral
12
Neoplasms
11
Lymphoma, T-Cell
9
Prostatic Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, T-Cell, Cutaneous
8
Immunoglobulin Light-chain Amyloidosis
8
Burkitt Lymphoma
8
Sezary Syndrome
7
Neoplasm, Residual
7
Mycosis Fungoides
7
Lymphoma, Large-Cell, Anaplastic
7
Leukemia, Plasma Cell
6
Interventions
poly(I).poly(c12,U)
1
pembrolizumab
1
mirabegron
1
liposomal doxorubicin
1
disitamab vedotin
1
apatinib
1
anlotinib
1
Tocotrienols
1
Platinum Compounds
1
Paclitaxel
1
Lenalidomide
1
Interferon alpha-2
1
Hyperthermic Intraperitoneal Chemotherapy
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Ovarian Cancer Recurrent
×
Lenalidomide
×
Clear all
NCT01111903
2016-03-17
REV
ARCAGY/ GINECO GROUP
Phase 1/2
Completed
67 enrolled